A practical reference on circadian clock: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-15. Anything still debated is marked as such rather than presented as settled.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
The liquid containing the analytes of interest (typically 10−6 - 10−4 M needed ) is dispersed by electrospray, into a fine aerosol. Because the ion formation involves extensive solvent evaporation (also termed desolvation), the typical solvents for electrospray ionization are prepared by mixing water with volatile organic compounds (e.g. methanol acetonitrile). To decrease the initial droplet size, compounds that increase the conductivity (e.g. acetic acid) are customarily added to the solution. These species also act to provide a source of protons to facilitate the ionization process. Large-flow electrosprays can benefit from nebulization of a heated inert gas such as nitrogen or carbon dioxide in addition to the high temperature of the ESI source. The aerosol is sampled into the first vacuum stage of a mass spectrometer through a capillary carrying a potential difference of approximately 3000 V, which can be heated to aid further solvent evaporation from the charged droplets. The solvent evaporates from a charged droplet until it becomes unstable upon reaching its Rayleigh limit. At this point, the droplet deforms as the electrostatic repulsion of like charges, in an ever-decreasing droplet size, becomes more powerful than the surface tension holding the droplet together. At this point the droplet undergoes Coulomb fission, whereby the original droplet 'explodes' creating many smaller, more stable droplets. The new droplets undergo desolvation and subsequently further Coulomb fissions.
== Structure == Motilin has 22 amino acids and molecular weight of 2698 daltons. In extract from human gut and plasma, there are two basic forms of motilin. The first molecular form is the polypeptide of 22 amino acids. The second form, on the other hand, is larger and contains the same 22 amino acids as the first form but includes an additional carboxyl-terminus end. The sequences of amino acids of motilin is: Phe-Val-Pro-Ile-Phe-Thr-Tyr-Gly-Glu-Leu-Gln-Arg-Met-Gln-Glu-Lys-Glu-Arg-Asn-Lys-Gly-Gln. The structure and dynamics of the gastrointestinal peptide hormone motilin have been studied in the presence of isotropic q = 0.5 phospholipid bicelles. The NMR solution structure of the peptide in acidic bicelle solution was determined from 203 NOE-derived distance constraints and six backbone torsion angle constraints. Dynamic properties for the 13Cα→1H vector in Leu-10 were determined for motilin specifically labeled with 13C at this position by analysis of multiple-field relaxation data. The structure reveals an ordered alpha-helical conformation between Glu-9 and Lys-20. The N-terminus is also well structured with a turn resembling that of a classical beta-turn. The 13C dynamics clearly show that motilin tumbles slowly in solution, with a correlation time characteristic of a large object.
=== Weight loss === Bupropion, when used for treating long-term weight gain over six to twelve months, results in an average weight loss of 2.7 kilograms (6.0 lb) compared to a placebo. This is not much different from the weight loss produced by several other weight-loss medications, such as sibutramine and orlistat. The combination drug naltrexone/bupropion has been approved by the US Food and Drug Administration (FDA) for the treatment of obesity.
Sources: en.wikipedia.org
==== Acquired abnormalities ==== Allergic and vasomotor rhinitis – inflammations of the mucous membrane of the nose caused by an allergen, and caused by circulatory and nervous system disorders. Autoimmune system diseases Bites – animal and human Burns – caused by chemicals, electricity, friction, heat, light, and radiation. Connective-tissue diseases Inflammatory conditions Nasal fractures Naso-orbito-ethmoidal fractures – damages to the nose and the eye-sockets; and damage to the bones and the walls of the nasal cavity; it is the ethmoid bone that separates the brain from the nose. Neoplasms – malignant and benign tumors Septal hematoma – a mass of (usually) clotted blood in the septum Toxins – chemical damages caused by inspired substances – e.g. powdered cocaine, aerosol antihistamine medications, et cetera. Traumatic deformities caused by blunt trauma, penetrating trauma, and blast trauma. Venereal infection – e.g., syphilis
The chain attempted to enter large European markets thanks to joints with KFC. In Germany the first non-military A&W restaurant opened in Garbsen near Hanover on May 27, 2003 followed by a second in Cologne in July. A third in Berlin was scheduled for early September. A&W opened its first outlet in Bangladesh on December 15, 2004. The outlet reportedly closed in 2024. Indonesia hit a record milestone, as the hundredth restaurant opened in Bintaro Utama on October 20, 2004. By the end of 2004, all A&W restaurants in the Philippines were closed. Most A&W stores that opened in the U.S. during Yum!'s ownership were co-branded with another of Yum!'s chains—Long John Silver's, Pizza Hut, Taco Bell, or KFC. In 2009, its operations in Southeast Asia were in a mixed situation. Operations in Indonesia and Bangladesh were thriving, while the restaurants in Thailand and Malaysia were facing uncertainties. The Malaysian franchisee KUB planned to increase the number of restaurants to 60, up from 37 in 2012, despite net losses of $1.5 million. For its 90th anniversary, A&W announced an expansion plan to open fifteen new drive-ins in a concept the chain dubbed "Three-D Drive In: Drive-In, Drive-Through, Dine-In". Growth was more expeted in the states of Wisconsin, Michigan and Oregon, where some of these Three-D units were set up in 2008.
==== Collaboration ==== By having exclusive contract with TWG since 2017, A Twosome Place has been aiming for the growing tea market. For the 20th anniversary, A Twosome Place have collaborated with Mardi Mercredi using yogurt in the menu to express the taste of spring. There are five different products being collaborated with Mardi Mercredi. Using the flower pattern, which is the signature pattern, A Twosome Place has prepared cups and water bottles as well as rugs for home decoration.
Sources: en.wikipedia.org
===== Efficacy ===== Sustained and significant improvement in FSFI scores throughout a 52-week extension was attained, indicating a high efficacy of the drug treating HSDD, most notably when anticipating the challenge in psychological distress.
One theory says the submarine sandwich was brought to the U.S. by Dominic Conti (1874–1954), an Italian immigrant who came to New York in the late-19th century. He supposedly named it "submarine roll" after seeing the recovered 1901 submarine called Fenian Ram in the Paterson Museum of New Jersey in 1928. His granddaughter said:
== Education and career == Wickramasinghe studied at Royal College, Colombo, the University of Ceylon (where he graduated in 1960 with a BSc First Class Honours in mathematics), and at Trinity College and Jesus College, Cambridge, where he obtained his PhD and ScD degrees. Following his education, Wickramasinghe was a Fellow of Jesus College, Cambridge from 1963 to 1973, then became professor of applied mathematics and astronomy at University College Cardiff. Wickramasinghe was a consultant and advisor to the President of Sri Lanka from 1982 to 1984, and played a key role in founding the Institute of Fundamental Studies in Sri Lanka. After fifteen years at University College Cardiff, Wickramasinghe took an equivalent position in the University of Cardiff, a post he held from 1990 until 2006. After retirement in 2006, he incubated the Cardiff Center for Astrobiology as a special project reporting to the president of the university. In 2011 the project closed down, losing its funding in a series of UK educational cut backs. After this event, Wickramasinghe was offered the opportunity to move to the University of Buckingham as Director of the Buckingham Centre for Astrobiology, University of Buckingham where he has been since 2011. He maintains his part-time position as a UK Professor at Cardiff University. In 2015 he was elected Visiting scholar, Churchill College, Cambridge, England for 2015 and 2016.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.